Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Apr;41(4):721–727. doi: 10.1128/aac.41.4.721

Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.

P D Lister 1, A M Prevan 1, C C Sanders 1
PMCID: PMC163782  PMID: 9087477

Abstract

An in vitro pharmacokinetic model was used to study the pharmacodynamics of piperacillin-tazobactam and piperacillin-sulbactam against gram-negative bacilli producing plasmid-encoded beta-lactamases. Logarithmic-phase cultures were exposed to peak antibiotic concentrations observed in human serum after the administration of intravenous doses of 3 g of piperacillin and 0.375 g of tazobactam or 0.5 g of sulbactam. Piperacillin and inhibitor were either dosed simultaneously or piperacillin was dosed sequentially 0.5 h after dosing with the inhibitor. In studies with all four test strains, the pharmacodynamics observed after simultaneous dosing were similar to those observed with the sequential regimen. Since the ratio between piperacillin and tazobactam was in constant fluctuation after sequential dosing, these data suggest that the pharmacodynamics of the piperacillin-inhibitor combinations were not dependent upon maintenance of a critical ratio between the components. Furthermore, when regrowth was observed, the time at which bacterial counts began to increase was similar between the simultaneous and sequential dosing regimens. Since the pharmacokinetics of the inhibitors were the same for all regimens, these data suggest that the length of time that the antibacterial activity was maintained over the dosing interval with these combinations was dictated by the pharmacokinetics of the beta-lactamase inhibitor in the combination. The antibacterial activity of the combination appeared to be lost when the amount of inhibitor available fell below some critical concentration. This critical concentration varied depending upon the type and amount of enzyme produced, as well as the specific inhibitor used. These results indicate that the antibacterial activity of drug-inhibitor combinations, when dosed at their currently recommended ratios, is more dependent on the pharmacokinetics of the inhibitor than on those of the beta-lactam drug.

Full Text

The Full Text of this article is available as a PDF (231.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexov M., Lister P. D., Sanders C. C. Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Antimicrob Agents Chemother. 1996 Nov;40(11):2468–2477. doi: 10.1128/aac.40.11.2468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blaser J., Stone B. B., Zinner S. H. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):131–137. doi: 10.1093/jac/15.suppl_a.131. [DOI] [PubMed] [Google Scholar]
  3. Bush K., Macalintal C., Rasmussen B. A., Lee V. J., Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993 Apr;37(4):851–858. doi: 10.1128/aac.37.4.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drusano G. L., Schimpff S. C., Hewitt W. L. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis. 1984 Jan-Feb;6(1):13–32. doi: 10.1093/clinids/6.1.13. [DOI] [PubMed] [Google Scholar]
  5. Eliopoulos G. M., Moellering R. C., Jr Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med. 1982 Nov;97(5):755–760. doi: 10.7326/0003-4819-97-5-755. [DOI] [PubMed] [Google Scholar]
  6. Fantin B., Pangon B., Potel G., Caron F., Vallée E., Vallois J. M., Mohler J., Buré A., Philippon A., Carbon C. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Antimicrob Agents Chemother. 1990 Apr;34(4):581–586. doi: 10.1128/aac.34.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S503–S511. doi: 10.1093/clinids/8.supplement_5.503. [DOI] [PubMed] [Google Scholar]
  8. Jones R. N., Pfaller M. A., Fuchs P. C., Aldridge K., Allen S. D., Gerlach E. H. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):489–494. [PubMed] [Google Scholar]
  9. Leleu G., Kitzis M. D., Vallois J. M., Gutmann L., Decazes J. M. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1994 Feb;38(2):195–199. doi: 10.1128/aac.38.2.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Murray P. R., Cantrell H. F., Lankford R. B. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group. Diagn Microbiol Infect Dis. 1994 Jun;19(2):111–120. doi: 10.1016/0732-8893(94)90121-x. [DOI] [PubMed] [Google Scholar]
  11. NOVICK R. P. Micro-iodometric assay for penicillinase. Biochem J. 1962 May;83:236–240. doi: 10.1042/bj0830236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sanders C. C., Sanders W. E., Jr, Moland E. S. Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother. 1986 Dec;30(6):951–952. doi: 10.1128/aac.30.6.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sanders W. E., Jr, Sanders C. C. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis. 1996 Jan;22(1):107–123. doi: 10.1093/clinids/22.1.107. [DOI] [PubMed] [Google Scholar]
  14. Strayer A. H., Gilbert D. H., Pivarnik P., Medeiros A. A., Zinner S. H., Dudley M. N. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct;38(10):2351–2356. doi: 10.1128/aac.38.10.2351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sörgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):39–60. doi: 10.1093/jac/31.suppl_a.39. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES